For your patients with 4-14 MHDs per month
Emgality significantly improved patients' migraine-specific quality of life during and in between attacks1,2
MSQ v2.1 RF-R scores are scaled from 0 to 100. Higher scores indicate less impact of migraine on daily activities.1
On the MSQ v2.1 RF-R, Emgality demonstrated a significantly greater mean improvement from baseline vs placebo over Months 4 to 6.1
In REGAIN, statistical significance vs placebo was not observed after controlling for multiple comparisons for mean change in MSQ v2.1 RF-R.1
SELECT IMPORTANT SAFETY INFORMATION
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
- Emgality. Prescribing Information. Lilly USA, LLC.
- Speck RM, Shalhoub H, Wyrwich KW, et al. Psychometric validation of the Role Function Restrictive domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine. Headache. 2019;59(5):756-774.